BLV Receptor-Binding Domain for CAT1 Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack accurate ligand targeting for the cationic L-amino acid transporter CAT1 in mammals, particularly humans, which is crucial for diagnosing and treating CAT1-related diseases such as cancer, diabetes, and inflammatory conditions, as existing strategies face resistance and side effects.
Innovation Solution
Employing a receptor-binding domain (RBD) derived from the bovine leukemia virus (BLV) envelope glycoprotein to specifically bind with CAT1, allowing for the detection and treatment of CAT1-related diseases by inhibiting arginine influx and using it for diagnostic and therapeutic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If arginine deprivation strategies are used to fight cancer, then arginine-related pathways are targeted, but resistance appears and side effects occur
Solution Approach 1:
The patent introduces BLV-RBD as an intermediary molecule that specifically binds to CAT1 transporter on cancer cells, blocking arginine uptake without directly depleting arginine systemically. This mediator approach allows targeted inhibition of arginine influx in tumor cells while sparing normal cells, thereby maintaining treatment efficacy while reducing side effects and resistance development.
Solution Approach 2:
The invention applies local quality by using BLV-RBD that specifically targets CAT1-expressing cancer cells through selective binding. The treatment effect is localized to cells with high CAT1 expression, allowing differential treatment where cancer cells receive arginine deprivation while normal cells maintain normal arginine metabolism, thus reducing harmful side effects.
2Measurement precision
If existing ligand targeting methods are used for CAT1, then arginine uptake can be inhibited, but accurate targeting of mammalian CAT1 (particularly human) is lacking
Solution Approach 1:
The patent demonstrates universality by showing that BLV-RBD derived from bovine leukemia virus can bind to CAT1 transporters across multiple species including human, cattle, and flock CAT1 with high affinity. This cross-species binding capability makes BLV-RBD a universal tool for both research and therapeutic applications in different mammalian systems, overcoming the limitation of species-specific targeting.
3Adaptability or versatility
If new strategies for CAT1 targeting are developed, then treatment options improve, but diagnostic methods for CAT1-related diseases remain limited
Solution Approach 1:
The patent employs BLV-RBD as a diagnostic intermediary that specifically binds to CAT1 on cell surfaces. This binding interaction can be detected using various detection methods (e.g., flow cytometry, immunofluorescence, ELISA), enabling researchers and clinicians to quantify CAT1 expression levels and identify CAT1-related diseases. The same mediator used for therapy also serves diagnostic purposes, integrating detection and treatment capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The BLV-RBD effectively blocks arginine accumulation in cells, providing a novel approach for diagnosing and treating CAT1-related diseases with potential for improved efficacy and reduced side effects compared to existing strategies.
Implementation Method 1
the inventors discovered that a ligand derived from the bovine leukemia virus (BLV) envelope glycoprotein bound specifically to CAT1 of different mammals including humans
Data Source
AI summary
Disclosed are methods for diagnosing CAT1-related diseases, wherein the methods include detecting CAT1 in a cell by a BLV.RBD ligand, or a variant or a fragment thereof. Also disclosed is a BLV.RBD ligand, or a variant or a fragment thereof for use in the treatment of CAT1-related diseases and/or BLV infections.